loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of All Manufacturers & Suppliers for 2286386 Licensing, EU CTD Dossiers, Marketing Authorizations, Finished Dosage Formulations listed on PharmaCompass.com

    Client Virtual Booth
    Menu

    Biogen

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 NATALIZUMAB (1)

    filter

    01 BIOGEN CANADA INC (1)

    filter

    01 SOLUTION (1)

    filter

    01 300MG/15ML (1)

    filter

    01 Canada (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
    • FDA
    • WHO-GMP
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Natalizumab

    PDF Supplier PDF
    URL Supplier Web Content
    SOLUTION
    300MG/15ML
    TYSABRI
    Canada
    2286386
    1VIAL
    Prescription
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for CTD TGA MCC DOSSIER APPLICATION 2286386

    Looking for CTD TGA MCC DOSSIER APPLICATION 2286386 1

    19

    Biogen, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and WHO-GMP.

    One of their notable products is NATALIZUMAB, with a corresponding application number 2286386 and regulatory information .

    proudly manufactured in the

    Biogen's TYSABRI SOLUTION, medication with 300MG/15ML of NATALIZUMAB.

    Post Enquiry
    POST ENQUIRY